ClinicalTrials.gg
Active, not recruitingNCT04305496CAPItello-291Updated Apr 30, 2026Results posted

Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer

A Phase 3 interventional study of Fulvestrant and Capivasertib in Locally Advanced (Inoperable) or Metastatic Breast Cancer, sponsored by AstraZeneca. Active, not recruiting at 215 sites in 19 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-04-30.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
818
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing capivasertib in Breast Neoplasms — 3 open to participants now, 13 under way, 7 of them phase 3. capivasertib · Breast Neoplasms.

Enrollment
7th of 20
818 · median 247
Started
2020
the only one that year
Phase 3
7 of 20
2 open now
Primary completion
2023-05
later than 2 of 12 live
Registered
12th of 20
by date
Lead sponsor
8 of 20
AstraZeneca

Among the 20 studies testing capivasertib in Breast Neoplasms, this one is the 7th largest by enrollment, is the only one that started in 2020, is one of 7 in phase 3, reaches primary completion later than 2 of the 12 other live ones, and was the 12th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

3 of the 20 studies testing capivasertib in Breast Neoplasms are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About capivasertib

capivasertib: first FDA approval 2023 (TRUQAP), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing capivasertib in Breast Neoplasms, or all of them as a file.
02

Study summary

Phase III, double-blind, randomised study assessing the efficacy of capivasertib + fulvestrant vs placebo + fulvestrant for the treatment of patients with locally advanced (inoperable) or metastatic HR+/HER2- breast cancer following recurrence or progression on or after AI therapy.

Read the detailed description

Phase III, double-blind, randomised study assessing the efficacy of capivasertib + fulvestrant vs placebo + fulvestrant for the treatment of patients with locally advanced (inoperable) or metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) breast cancer following recurrence or progression on or after aromatase inhibitor (AI) therapy.

03

Conditions studied

  • Locally Advanced (Inoperable) or Metastatic Breast Cancer

Browse trials for

Keywords

  • Locally advanced (inoperable) or Metastatic Breast Cancer
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult females, pre- and/or , and adult males. Pre-menopausal (and peri-menopausal) women can be enrolled if amenable to treatment with an LHRH agonist. Patients are to have commenced concomitant treatment with LHRH agonist prior to or on Cycle 1, Day 1 and must be willing to continue on it for the duration of the study
  2. confirmed HR+/- breast cancer determined from the most recent tumour sample (primary or ), as per the American Society of Clinical Oncology and College of American Pathologists guideline recommendations. To fulfil the requirement of HR+ disease, a breast cancer must express ER with or without co-expression of progesterone receptor.
  3. Metastatic or locally advanced disease with radiological or objective evidence of recurrence or progression (the cancer should have shown progression during or after most recent therapy); locally advanced disease must not be amenable to resection with curative intent (patients who are considered suitable for surgical or ablative techniques following potential down-staging with study treatment are not eligible)
  4. PS: 0-1
  5. Patients are to have received treatment with an AI (aromatase inhibitor) containing regimen (single agent or in combination) and have:

    1. Radiological evidence of breast cancer recurrence or progression while on, or within 12 months of the end of (neo) treatment with an AI, OR
    2. Radiological evidence of progression while on prior AI administered as a treatment line for locally advanced or metastatic breast cancer (this does not need to be the most recent therapy)
  6. Patients must have according to 1.1 and/or at least 1 lytic or mixed (lytic + sclerotic) bone lesion that can be assessed by CT or MRI; patients with sclerotic/osteoblastic bone lesions only in the absence of measurable disease are not eligible
  7. FFPE tumour sample from primary/recurrent cancer for central testing

Exclusion criteria

Exclusion Criteria:

  1. Symptomatic visceral disease or any disease burden that makes the patient ineligible for endocrine therapy per the investigator's best judgement
  2. More than 2 lines of endocrine therapy for inoperable locally advanced or disease
  3. More than 1 for inoperable locally advanced or metastatic disease. and neoadjuvant chemotherapy are not classed as lines of chemotherapy for advanced breast cancer
  4. Prior treatment with any of the following:

    1. AKT, PI3K and mTOR inhibitors
    2. Fulvestrant, and other SERDs
    3. Any other chemotherapy, immunotherapy, medication (other than ) or anticancer agents within 3 weeks prior to study treatment initiation.
    4. Potent inhibitors or inducers of within 2 weeks prior to the first dose of study treatment (3 weeks for St John's wort) or drugs that are sensitive to CYP3A4 inhibition within 1 week prior to study treatment initiation.
  5. Radiotherapy with a wide field of radiation up to 4 weeks before study treatment initiation (capivasertib/placebo) and/or radiotherapy with a limited field of radiation for palliation up to 2 weeks before study treatment initiation (capivasertib/placebo)
  6. With the exception of alopecia, any unresolved toxicities from prior therapy greater than grade 1 at the time of starting study treatment
  7. Spinal cord compression or unless asymptomatic, treated and stable and not requiring steroids up to 4 weeks before study treatment initiation
  8. Any of the following cardiac criteria:

    1. Mean resting corrected by Fridericia's formula (QTcF) >470 msec obtained from 3 consecutive ECGs
    2. Any abnormalities in rhythm, conduction or morphology of resting (eg, complete left bundle branch block, third degree heart block)
    3. Any factors that increase the risk of corrected QT interval (QTc) prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, potential for torsades de pointes, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age or any concomitant medication known to prolong the QT interval
    4. Experience of any of the following procedures or conditions in the preceding 6 months: coronary artery bypass graft, angioplasty, vascular stent, myocardial infarction, angina pectoris, congestive heart failure (NYHA) grade ≥2
    5. Uncontrolled hypotension - systolic blood pressure \<90 mmHg and/or diastolic blood pressure \<50 mmHg
    6. Cardiac outside institutional range of normal or \<50% (whichever is higher) as measured by echocardiogram (or multiple-gated acquisition [MUGA] scan if an echocardiogram cannot be performed or is inconclusive)
  9. Clinically significant abnormalities of glucose metabolism as defined by any of the following:

    1. Patients with diabetes mellitus type 1 or diabetes mellitus type 2 requiring insulin treatment
    2. ≥8.0% (63.9 mmol/mol)
  10. Known abnormalities in coagulation such as bleeding diathesis, or treatment with anticoagulants precluding intramuscular injections of fulvestrant or LHRH agonist (if applicable)
  11. Currently pregnant (confirmed with positive pregnancy test) or breast-feeding
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
818 participants (actual)

Study arms

  • Experimental
    Capivasertib + fulvestrant

    Fulvestrant: 2 intramuscular injections of 500 mg given on Day 1 of Weeks 1 and 3 of cycle 1, and then on Day 1, Week 1 of each cycle thereafter. Capivasertib: 400 mg (2 oral tablets) BD given on an intermittent weekly dosing schedule. Dosed on Days 1 to 4 in each week of a 28-day treatment cycle.

    Drug: Fulvestrant · Drug: Capivasertib

  • Placebo comparator
    Placebo + fulvestrant

    Fulvestrant: 2 intramuscular injections of 500 mg given on Day 1 of Weeks 1 and 3 of cycle 1, and then on Day 1, Week 1 of each cycle thereafter. Placebo: 400 mg (2 oral tablets) BD given on an intermittent weekly dosing schedule. Dosed on Days 1 to 4 in each week of a 28-day treatment cycle.

    Drug: Fulvestrant · Drug: Placebo

Interventions

  • Patients will be administered 500 mg (2 injections) on Day 1 of Weeks 1 and 3 of Cycle 1, and then on Day 1, Week 1 of each cycle thereafter

  • 400 mg BD (2 tablets of 200 mg taken twice a day = total daily dose 800 mg) given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week of a 28-day treatment cycle

  • DrugPlacebo

    Placebo to match 400 mg BD (2 tablets of placebo to match 200 mg taken twice daily = placebo to match total daily dose of 800 mg) given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week of a 28-day treatment cycle

06

What researchers measure

Primary outcomes

  1. Progression Free Survival: Overall Population (Months) in the Global Cohort

    Progression free survival (PFS), defined as the time from randomization until progression per RECIST v1.1, as assessed by the investigator at the local site, or death due to any cause, in the global cohort. Participants who discontinue treatment prior to progression should continue to be scanned until progression. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) as at least a 20% increase in the sum of the longest diameter of target lesions (short axis diameter used for lymph nodes), or clinically significant increase in a non-target lesion, or the appearance of a new lesion(s).

    Time frame: Assessed every 8 weeks for the first 18 months and every 12 weeks thereafter, from randomization to radiological progression.

  2. Progression Free Survival: Overall Population (Percentage) in the Global Cohort

    Progression free survival (PFS), defined as the time from randomization until progression per RECIST v1.1, as assessed by the investigator at the local site, or death due to any cause. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) as at least a 20% increase in the sum of the longest diameter of target lesions (short axis diameter used for lymph nodes), or clinically significant increase in a non-target lesion, or the appearance of a new lesion(s). Participants who discontinue treatment prior to progression should continue to be scanned until progression. Kaplan-Meier estimate was used.

    Time frame: Assessed every 8 weeks for the first 18 months and every 12 weeks thereafter, from randomization to radiological progression.

  3. Progression Free Survival: Altered Population (Months) in the Global Cohort

    Progression free survival (PFS), defined as the time from randomization until progression per RECIST v1.1, as assessed by the investigator at the local site, or death due to any cause.

    Time frame: Assessed every 8 weeks for the first 2 years following objective disease progression or treatment discontinuation and then every 12 weeks.

  4. Progression Free Survival: Altered Population (Percentage) in the Global Cohort

    Progression free survival (PFS), defined as the time from randomization until progression per RECIST v1.1, as assessed by the investigator at the local site, or death due to any cause. Kaplan-Meier estimate was used.

    Time frame: Assessed every 8 weeks for the first 2 years following objective disease progression or treatment discontinuation and then every 12 weeks.

  5. Progression Free Survival: Overall Population (Months) in the China Cohort

    Progression free survival (PFS), defined as the time from randomization until progression per RECIST v1.1, as assessed by the investigator at the local site, or death due to any cause, in the global cohort. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) as at least a 20% increase in the sum of the longest diameter of target lesions (short axis diameter used for lymph nodes), or clinically significant increase in a non-target lesion, or the appearance of a new lesion(s). Participants who discontinue treatment prior to progression should continue to be scanned until progression.

    Time frame: Assessed every 8 weeks for the first 18 months and every 12 weeks thereafter, from randomization to radiological progression.

  6. Progression Free Survival: Overall Population (Percentage) in the China Cohort

    Progression free survival (PFS), defined as the time from randomization until progression per RECIST v1.1, as assessed by the investigator at the local site, or death due to any cause. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) as at least a 20% increase in the sum of the longest diameter of target lesions (short axis diameter used for lymph nodes), or clinically significant increase in a non-target lesion, or the appearance of a new lesion(s). Participants who discontinue treatment prior to progression should continue to be scanned until progression. Kaplan-Meier estimate was used.

    Time frame: Assessed every 8 weeks for the first 18 months and every 12 weeks thereafter, from randomization to radiological progression.

  7. Progression Free Survival: Altered Population (Months) in the China Cohort

    Progression free survival (PFS), defined as the time from randomization until progression per RECIST v1.1, as assessed by the investigator at the local site, or death due to any cause.

    Time frame: Assessed every 8 weeks for the first 2 years following objective disease progression or treatment discontinuation and then every 12 weeks.

  8. Progression Free Survival: Altered Population (Percentage) in the China Cohort

    Progression free survival (PFS), defined as the time from randomization until progression per RECIST v1.1, as assessed by the investigator at the local site, or death due to any cause Kaplan-Meier estimate was used.

    Time frame: Assessed every 8 weeks for the first 2 years following objective disease progression or treatment discontinuation and then every 12 weeks.

07

Results

Posted Oct 27, 2025
Limitations and caveats
There were 24 participants who were included in both the global cohort and China cohort which gives a total of 818 participants instead of a total of 842 participants.

Participant flow

A total of 708 participants in Global cohort (out of 818 participants in Global and China cohorts) were randomized to treatment. An additional 110 participants were enrolled into the China cohort only.

Global Cohort
Participant flow — Global Cohort
MilestoneCapivasertib + FulvestrantPlacebo + Fulvestrant
Started355353
Completed6343
Not completed292310
Withdrew: Withdrawal by subject136
Withdrew: Physician decision11
Withdrew: Subjective disease progression1617
Withdrew: Condition under investigation worsened209273
Withdrew: Protocol violation20
Withdrew: Adverse event446
Withdrew: Death32
Withdrew: Any reason not specifically recorded45
China Cohort
Participant flow — China Cohort
MilestoneCapivasertib + FulvestrantPlacebo + Fulvestrant
Started7163
Completed1810
Not completed5353
Withdrew: Any reason not specifically recorded11
Withdrew: Adverse event82
Withdrew: Condition under investigation worsened4047
Withdrew: Subjective disease progression22
Withdrew: Withdrawal by subject21

Outcome measures

PrimaryProgression Free Survival: Overall Population (Months) in the Global Cohort

Progression free survival (PFS), defined as the time from randomization until progression per RECIST v1.1, as assessed by the investigator at the local site, or death due to any cause, in the global cohort. Participants who discontinue treatment prior to progression should continue to be scanned until progression. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) as at least a 20% increase in the sum of the longest diameter of target lesions (short axis diameter used for lymph nodes), or clinically significant increase in a non-target lesion, or the appearance of a new lesion(s).

Time frame:
Assessed every 8 weeks for the first 18 months and every 12 weeks thereafter, from randomization to radiological progression.
Reported as:
Median · Months
Progression Free Survival: Overall Population (Months) in the Global Cohort
MonthsCapivasertib + Fulvestrant (Global + China Cohort)Placebo + Fulvestrant (Global + China Cohort)
Progression Free Survival: Overall Population (Months) in the Global Cohort7.2 (5.5 to 7.4)3.6 (2.8 to 3.7)
Statistical analysis
  • Capivasertib + Fulvestrant (Global + China Cohort) vs Placebo + Fulvestrant (Global + China Cohort) · Stratified log rank test · p = <0.001 · Hazard ratio (hr): 0.60 · 95% CI 0.51 to 0.71
PrimaryProgression Free Survival: Overall Population (Percentage) in the Global Cohort

Progression free survival (PFS), defined as the time from randomization until progression per RECIST v1.1, as assessed by the investigator at the local site, or death due to any cause. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) as at least a 20% increase in the sum of the longest diameter of target lesions (short axis diameter used for lymph nodes), or clinically significant increase in a non-target lesion, or the appearance of a new lesion(s). Participants who discontinue treatment prior to progression should continue to be scanned until progression. Kaplan-Meier estimate was used.

Time frame:
Assessed every 8 weeks for the first 18 months and every 12 weeks thereafter, from randomization to radiological progression.
Reported as:
Number · Percentage of participants
Progression Free Survival: Overall Population (Percentage) in the Global Cohort
Percentage of participantsCapivasertib + Fulvestrant (Global + China Cohort)Placebo + Fulvestrant (Global + China Cohort)
PFS rate at 6 months51.8 (46.4 to 57.0)32.0 (27.0 to 37.0)
PFS rate at 9 months40.9 (35.6 to 46.1)24.4 (19.9 to 29.1)
PFS rate at 12 months28.5 (23.7 to 33.5)18.4 (14.4 to 22.8)
Statistical analysis
  • Capivasertib + Fulvestrant (Global + China Cohort) · Stratified log rank test · p = <0.001 · Hazard ratio (hr): 0.60 · 95% CI 0.51 to 0.71
PrimaryProgression Free Survival: Altered Population (Months) in the Global Cohort

Progression free survival (PFS), defined as the time from randomization until progression per RECIST v1.1, as assessed by the investigator at the local site, or death due to any cause.

Time frame:
Assessed every 8 weeks for the first 2 years following objective disease progression or treatment discontinuation and then every 12 weeks.
Reported as:
Median · Months
Progression Free Survival: Altered Population (Months) in the Global Cohort
MonthsCapivasertib + Fulvestrant (Global + China Cohort)Placebo + Fulvestrant (Global + China Cohort)
Progression Free Survival: Altered Population (Months) in the Global Cohort7.3 (5.5 to 9.0)3.1 (2.0 to 3.7)
Statistical analysis
  • Capivasertib + Fulvestrant (Global + China Cohort) vs Placebo + Fulvestrant (Global + China Cohort) · Stratified log-rank test · p = <0.001 · Hazard ratio (hr): 0.50 · 95% CI 0.38 to 0.65
PrimaryProgression Free Survival: Altered Population (Percentage) in the Global Cohort

Progression free survival (PFS), defined as the time from randomization until progression per RECIST v1.1, as assessed by the investigator at the local site, or death due to any cause. Kaplan-Meier estimate was used.

Time frame:
Assessed every 8 weeks for the first 2 years following objective disease progression or treatment discontinuation and then every 12 weeks.
Reported as:
Number · Percentage of participants
Progression Free Survival: Altered Population (Percentage) in the Global Cohort
Percentage of participantsCapivasertib + Fulvestrant (Global + China Cohort)Placebo + Fulvestrant (Global + China Cohort)
PFS rate at 6 months53.4 (45.1 to 60.9)29.6 (21.9 to 37.7)
PFS rate at 9 months42.0 (34.0 to 49.7)21.6 (14.9 to 29.1)
PFS rate at 12 months28.2 (21.2 to 35.6)15.8 (10.0 to 22.7)
Statistical analysis
  • Capivasertib + Fulvestrant (Global + China Cohort) vs Placebo + Fulvestrant (Global + China Cohort) · Stratified log-rank test · p = <0.001 · Hazard ratio (hr): 0.50 · 95% CI 0.38 to 0.65
PrimaryProgression Free Survival: Overall Population (Months) in the China Cohort

Progression free survival (PFS), defined as the time from randomization until progression per RECIST v1.1, as assessed by the investigator at the local site, or death due to any cause, in the global cohort. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) as at least a 20% increase in the sum of the longest diameter of target lesions (short axis diameter used for lymph nodes), or clinically significant increase in a non-target lesion, or the appearance of a new lesion(s). Participants who discontinue treatment prior to progression should continue to be scanned until progression.

Time frame:
Assessed every 8 weeks for the first 18 months and every 12 weeks thereafter, from randomization to radiological progression.
Reported as:
Median · Months
Progression Free Survival: Overall Population (Months) in the China Cohort
MonthsCapivasertib + Fulvestrant (Global + China Cohort)Placebo + Fulvestrant (China Cohort)
Progression Free Survival: Overall Population (Months) in the China Cohort6.9 (5.4 to 9.2)2.8 (1.9 to 3.9)
Statistical analysis
  • Capivasertib + Fulvestrant (Global + China Cohort) · Stratified log rank test · p = <0.001 · Hazard ratio (hr): 0.51 · 95% CI 0.34 to 0.76
PrimaryProgression Free Survival: Overall Population (Percentage) in the China Cohort

Progression free survival (PFS), defined as the time from randomization until progression per RECIST v1.1, as assessed by the investigator at the local site, or death due to any cause. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) as at least a 20% increase in the sum of the longest diameter of target lesions (short axis diameter used for lymph nodes), or clinically significant increase in a non-target lesion, or the appearance of a new lesion(s). Participants who discontinue treatment prior to progression should continue to be scanned until progression. Kaplan-Meier estimate was used.

Time frame:
Assessed every 8 weeks for the first 18 months and every 12 weeks thereafter, from randomization to radiological progression.
Reported as:
Number · Percentage of participants
Progression Free Survival: Overall Population (Percentage) in the China Cohort
Percentage of participantsCapivasertib + Fulvestrant (Global + China Cohort)Placebo + Fulvestrant (China Cohort)
PFS rate at 6 months53.9 (41.3 to 65.0)24.5 (14.6 to 35.8)
PFS rate at 9 months40.9 (28.8 to 52.5)24.5 (14.6 to 35.8)
PFS rate at 12 months29.6 (18.6 to 41.4)19.1 (10.3 to 29.9)
Statistical analysis
  • Capivasertib + Fulvestrant (Global + China Cohort) · Stratified log rank test · p = <0.001 · Hazard ratio (hr): 0.51 · 95% CI 0.34 to 0.76
PrimaryProgression Free Survival: Altered Population (Months) in the China Cohort

Progression free survival (PFS), defined as the time from randomization until progression per RECIST v1.1, as assessed by the investigator at the local site, or death due to any cause.

Time frame:
Assessed every 8 weeks for the first 2 years following objective disease progression or treatment discontinuation and then every 12 weeks.
Reported as:
Median · Months
Progression Free Survival: Altered Population (Months) in the China Cohort
MonthsCapivasertib + Fulvestrant (Global + China Cohort)Placebo + Fulvestrant (Global + China Cohort)
Progression Free Survival: Altered Population (Months) in the China Cohort5.7 (3.8 to 8.0)1.9 (1.8 to 3.7)
Statistical analysis
  • Capivasertib + Fulvestrant (Global + China Cohort) · Stratified log rank test · p = 0.016 · Hazard ratio (hr): 0.41 · 95% CI 0.19 to 0.85
PrimaryProgression Free Survival: Altered Population (Percentage) in the China Cohort

Progression free survival (PFS), defined as the time from randomization until progression per RECIST v1.1, as assessed by the investigator at the local site, or death due to any cause Kaplan-Meier estimate was used.

Time frame:
Assessed every 8 weeks for the first 2 years following objective disease progression or treatment discontinuation and then every 12 weeks.
Reported as:
Number · Percentage of participants
Progression Free Survival: Altered Population (Percentage) in the China Cohort
Percentage of participantsCapivasertib + Fulvestrant (Global + China Cohort)Placebo + Fulvestrant (Global + China Cohort)
PFS rate at 6 months46.3 (25.1 to 65.1)14.3 (3.6 to 32.1)
PFS rate at 9 months23.1 (8.5 to 42.0)14.3 (3.6 to 32.1)
PFS rate at 12 months6.9 (0.6 to 24.9)14.3 (3.6 to 32.1)
Statistical analysis
  • Capivasertib + Fulvestrant (Global + China Cohort) · Stratified log rank test · p = 0.016 · Hazard ratio (hr): 0.41 · 95% CI 0.19 to 0.85

Adverse events

Collected over Adverse events (AEs) and serious adverse events (SAEs) were collected from time of signature of the informed consent form, throughout the treatment period and including the 30-day follow-up period after discontinuation of study drug. Only treatment emergent AEs are presented.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Capi (Global Cohort)4/355 (1.1%)57/355 (16.1%)334/355 (94.1%)
Placebo (Global Cohort)1/350 (0.3%)28/350 (8%)255/350 (72.9%)
Capi (China Cohort)1/71 (1.4%)20/71 (28.2%)67/71 (94.4%)
Placebo (China Cohort)0/62 (0%)3/62 (4.8%)52/62 (83.9%)
Most frequent serious events
Showing 10 of 93
Most frequent serious events
EventCapi (Global Cohort)Placebo (Global Cohort)Capi (China Cohort)Placebo (China Cohort)
Rash maculo-papularSkin and subcutaneous tissue disorders5/3550/3503/710/62
Erythema multiformeSkin and subcutaneous tissue disorders1/3550/3502/710/62
VomitingGastrointestinal disorders4/3552/3502/710/62
DiarrhoeaGastrointestinal disorders6/3551/3500/710/62
AnaemiaBlood and lymphatic system disorders0/3551/3500/711/62
Drug-induced liver injuryHepatobiliary disorders1/3551/3500/711/62
Hepatic function abnormalHepatobiliary disorders0/3550/3500/711/62
Pericardial effusionCardiac disorders0/3550/3500/711/62
VertigoEar and labyrinth disorders0/3550/3501/710/62
Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/3550/3501/710/62
Most frequent other events
Showing 10 of 65
Most frequent other events
EventCapi (Global Cohort)Placebo (Global Cohort)Capi (China Cohort)Placebo (China Cohort)
DiarrhoeaGastrointestinal disorders255/35570/35043/717/62
HyperglycaemiaMetabolism and nutrition disorders56/35513/35041/7111/62
NauseaGastrointestinal disorders122/35553/35010/712/62
Alanine aminotransferase increasedInvestigations32/35530/35013/7121/62
AnaemiaBlood and lymphatic system disorders37/35516/35022/7111/62
RashSkin and subcutaneous tissue disorders77/35515/35021/714/62
Aspartate aminotransferase increasedInvestigations33/35533/35010/7118/62
Rash maculo-papularSkin and subcutaneous tissue disorders52/3559/35018/712/62
HypokalaemiaMetabolism and nutrition disorders15/3552/35018/716/62
Weight decreasedInvestigations12/3558/35017/713/62

Baseline characteristics

Full analysis set. 24 participants (16 participants in the capivasertib arm and 8 participants in the placebo arm) were included in both the Global and China cohorts.

Age, Continuous
Age, Continuous(years)Capivasertib + Fulvestrant (Global + China Cohort)Placebo + Fulvestrant (Global Cohort + China Cohort )Total
Global cohort58.6 ± 11.2557.4 ± 11.9158.0 ± 11.59
China cohort54.7 ± 10.6655.0 ± 10.6054.8 ± 10.59
Age, Customized
Age, Customized(Participants)Capivasertib + Fulvestrant (Global + China Cohort)Placebo + Fulvestrant (Global Cohort + China Cohort )Total
Global cohort — <50 years7699175
Global cohort — >=50-<65 years164152316
Global cohort — >=65-<75 years9176167
Global cohort — >=75 years242650
China cohort — <50 years192443
China cohort — >=50-<65 years392160
China cohort — >=65-<75 years121830
China cohort — >=75 years101
Sex: Female, Male
Sex: Female, Male(Participants)Capivasertib + Fulvestrant (Global + China Cohort)Placebo + Fulvestrant (Global Cohort + China Cohort )Total
Global cohort — Female352349701
Global cohort — Male347
China cohort — Female7162133
China cohort — Male011
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Capivasertib + Fulvestrant (Global + China Cohort)Placebo + Fulvestrant (Global Cohort + China Cohort )Total
Global cohort — Hispanic or Latino313162
Global cohort — Not Hispanic or Latino323322645
Global cohort — Unknown or Not Reported101
China cohort — Hispanic or Latino000
China cohort — Not Hispanic or Latino6961130
China cohort — Unknown or Not Reported224
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Capivasertib + Fulvestrant (Global + China Cohort)Placebo + Fulvestrant (Global Cohort + China Cohort )Total
Global cohort — American Indian or Alaska Native224
Global cohort — Asian9594189
Global cohort — Native Hawaiian or Other Pacific Islander101
Global cohort — Black or African American448
Global cohort — White201206407
Global cohort — More than one race000
Global cohort — Unknown or Not Reported524799
China cohort — American Indian or Alaska Native000
China cohort — Asian6961130
China cohort — Native Hawaiian or Other Pacific Islander000
China cohort — Black or African American000
China cohort — White000
China cohort — More than one race000
China cohort — Unknown or Not Reported224
08

Study locations

215 sites
  • Research Site
    Gilbert, Arizona 85234, United States
  • Research Site
    Orange, California 92868, United States
  • Research Site
    San Francisco, California 94143, United States
  • Research Site
    Whittier, California 90603, United States
  • Research Site
    Fort Myers, Florida 33905, United States
  • Research Site
    Jacksonville, Florida 32224, United States
  • Research Site
    Westwood, Kansas 66205, United States
  • Research Site
    Baltimore, Maryland 21201, United States
  • Research Site
    Boston, Massachusetts 02111-1520, United States
  • Research Site
    Rochester, Minnesota 55905, United States
  • Research Site
    Kansas City, Missouri 64132, United States
  • Research Site
    St Louis, Missouri 63156, United States
  • Research Site
    Paramus, New Jersey 07652, United States
  • Research Site
    Farmington, New Mexico 87401, United States
  • Research Site
    Lake Success, New York 11042, United States
  • Research Site
    New York, New York 10011, United States
  • Research Site
    Greensboro, North Carolina 27403, United States
  • Research Site
    Chattanooga, Tennessee 37404, United States
  • Research Site
    Nashville, Tennessee 37211, United States
  • Research Site
    Dallas, Texas 75246, United States
  • Research Site
    Midlothian, Virginia 23114, United States
  • Research Site
    Puyallup, Washington 98373, United States
  • Research Site
    Berazategui, B1884BBF, Argentina
  • Research Site
    Buenos Aires, C1125ABD, Argentina
  • Research Site
    La Rioja, 5300, Argentina
  • Research Site
    Rosario, S2000KZE, Argentina
  • Research Site
    Viedma, R8500ACE, Argentina
  • Research Site
    Adelaide, 5000, Australia
  • Research Site
    Ballarat, 3350, Australia
  • Research Site
    Birtinya, 4575, Australia
  • Research Site
    Box Hill, 3128, Australia
  • Research Site
    Concord, 2139, Australia
  • Research Site
    Kurralta Park, 5037, Australia
  • Research Site
    North Sydney, 2060, Australia
  • Research Site
    Orange, 2800, Australia
  • Research Site
    Ringwood East, 3135, Australia
  • Research Site
    South Brisbane, 4101, Australia
  • Research Site
    Waratah, 2298, Australia
  • Research Site
    Wendouree, 3355, Australia
  • Research Site
    Brussels, 1090, Belgium
  • Research Site
    Brussels, 1200, Belgium
  • Research Site
    Charleroi, 6000, Belgium
  • Research Site
    Edegem, 2650, Belgium
  • Research Site
    Namur, 5000, Belgium
  • Research Site
    Wilrijk, 2610, Belgium
  • Research Site
    Winnipeg, Manitoba R3E 0V9, Canada
  • Research Site
    Kingston, Ontario K7L 2V7, Canada
  • Research Site
    North York, Ontario M2K 1E1, Canada
  • Research Site
    Toronto, Ontario M3M 0B2, Canada
  • Research Site
    Toronto, Ontario M4N 3M5, Canada
  • Research Site
    Baoding, 071000, China
  • Research Site
    Beijing, 100044, China
  • Research Site
    Beijing, 100191, China
  • Research Site
    Changchun, 130021, China
  • Research Site
    Chongqing, 400030, China
  • Research Site
    Chongqing, 400042, China
  • Research Site
    Dalian, 116011, China
  • Research Site
    Foshan, 528000, China
  • Research Site
    Gongshu District, 310022, China
  • Research Site
    Guangzhou, 510080, China
  • Research Site
    Guangzhou, 510095, China
  • Research Site
    Hangzhou, 310003, China
  • Research Site
    Hangzhou, 310020, China
  • Research Site
    Harbin, 150081, China
  • Research Site
    Hefei, 230001, China
  • Research Site
    Hefei, 230022, China
  • Research Site
    Jinan, 250001, China
  • Research Site
    Linyi, 276001, China
  • Research Site
    Nanchang, 330009, China
  • Research Site
    Nantong, 226001, China
  • Research Site
    Neijiang, 641000, China
  • Research Site
    Shanghai, 200032, China
  • Research Site
    Shanghai, 200127, China
  • Research Site
    Shantou, 515031, China
  • Research Site
    Shenyang, 110001, China
  • Research Site
    Shenyang, 110042, China
  • Research Site
    Wuhan, 430022, China
  • Research Site
    Wuhan, 430030, China
  • Research Site
    Wuhan, 430079, China
  • Research Site
    Zhengzhou, 450008, China
  • Research Site
    Besançon, 25000, France
  • Research Site
    Brest, 29609, France
  • Research Site
    Metz, 57085, France
  • Research Site
    Pierre-Bénite, 69310, France
  • Research Site
    Plerin SUR MER, 22190, France
  • Research Site
    Pringy, 74374, France
  • Research Site
    Rouen, 76038, France
  • Research Site
    Strasbourg, 67065, France
  • Research Site
    Toulouse, 31059, France
  • Research Site
    Dresden, 01307, Germany
  • Research Site
    Erlangen, 91054, Germany
  • Research Site
    Essen, 45130, Germany
  • Research Site
    Frankfurt, 60389, Germany
  • Research Site
    Gelsenkirchen, 45879, Germany
  • Research Site
    Hamburg, 20246, Germany
  • Research Site
    Hamburg, 20249, Germany
  • Research Site
    Hamburg, 20357, Germany
  • Research Site
    Hanover, 30625, Germany
  • Research Site
    Heidelberg, 69120, Germany
  • Research Site
    Kiel, 24105, Germany

Showing the first 100 of 215 sites across 19 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, Hu X, Jhaveri K, Krivorotko P, Loibl S, Morales Murillo S, Okera M, Park YH, Sohn J, Toi M, Tokunaga E, Yousef S, Zhukova L, de Bruin EC, Grinsted L, Schiavon G, Foxley A, Rugo HS; CAPItello-291 Study Group. Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2023 Jun 1;388(22):2058-2070. doi: 10.1056/NEJMoa2214131. PubMed 37256976 ↗
  • Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez HL, Hu X, Jhaveri K, Krivorotko P, Loibl S, Murillo SM, Park YH, Sohn JH, Toi M, Tokunaga E, Yousef S, Zhukova L, de Bruin E, Grinsted L, Schiavon G, Foxley A, Rugo HS. A plain language summary of the CAPItello-291 study: Capivasertib in hormone receptor-positive advanced breast cancer. Future Oncol. 2024;20(37):2901-2913. doi: 10.1080/14796694.2024.2390791. Epub 2024 Sep 16. PubMed 39283299 ↗
  • Oliveira M, Rugo HS, Howell SJ, Dalenc F, Cortes J, Gomez HL, Hu X, Toi M, Jhaveri K, Krivorotko P, Loibl S, Morales Murillo S, Okera M, Nowecki Z, Park YH, Sohn JH, Tokunaga E, Yousef S, Zhukova L, Fulford M, Andrews H, Wadsworth I, D'Cruz C, Turner NC; CAPItello-291 study group. Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2024 Sep;25(9):1231-1244. doi: 10.1016/S1470-2045(24)00373-5. PubMed 39214106 ↗
  • Dilawari A, Buturla J, Osgood C, Gao X, Chen W, Ricks TK, Schaefer T, Avasarala S, Reyes Turcu F, Pathak A, Kalavar S, Bhatnagar V, Collazo J, Rahman NA, Mixter B, Tang S, Pazdur R, Kluetz P, Amiri-Kordestani L. US Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer With PIK3CA/AKT1/PTEN Alterations. J Clin Oncol. 2024 Dec;42(34):4103-4113. doi: 10.1200/JCO.24.00427. Epub 2024 Aug 19. PubMed 39159418 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2020 to primary completion in May 2023, 36 months.

Results were first posted in Oct 2025, 2 years 5 months after primary completion.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 36 months is close to that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2020
First posted
Mar 12, 2020
StartActual
Apr 16, 2020
Primary completionActual
May 9, 2023
CompletionEst.
Jun 22, 2026
Results first posted
Oct 27, 2025
Last update
Apr 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04305496
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Mar 12, 2020
Start date
Apr 16, 2020
Primary completion
May 9, 2023
Completion
Jun 22, 2026 (estimated)
Results posted
Oct 27, 2025
Last update
Apr 30, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Capivasertib

Start the discussion